As clinical trial team members seek to balance the eternal yin and yang of research projects’ often cold and technological-, regulatory-, and protocol-driven side vs. their very warm and human outreach-, recruitment-, and retention-focused elements, contributors to the next issue of ACRP’s Clinical Researcher journal remind readers that patient centricity must never be an afterthought in the pursuit of medical breakthroughs.
In her peer-reviewed article on “The Inclusive Clinical Trials: How Natural Market Trends and Intentional Operational Pivots are Needed for Clinical Product Development Success,” Vaidehi Agrawal, PhD, a Senior Director of Clinical Operations for a Maryland-based contract research organization, notes that inclusive clinical trials are increasingly recognized as a critical determinant of both scientific validity and commercial success in clinical product development.
“Inclusive trials are those that are intentionally designed and executed to ensure meaningful participation from diverse patient populations across geography, socioeconomic context, and biological or genetic variability, so that the evidence generated is both generalizable and clinically relevant,” Agrawal writes. “Access remains one of the most persistent barriers to inclusive clinical research. Long before diversity became a formal regulatory priority, many patients were excluded from trials simply because they lacked proximity to a trial site, the ability to travel frequently, or the flexibility to accommodate rigid visit schedules, ultimately resulting in commercial failure of specific therapeutics within specific markets.”
Inclusivity must be intentionally embedded into trial design, site strategy, and operational execution from the outset, Agrawal notes later in her article. “As clinical development becomes more global, decentralized, and data-driven, inclusive trials will increasingly distinguish programs that succeed from those that struggle to translate efficacy into real-world impact,” she adds. “The ability to design and deliver trials that reflect the diversity of the populations they intend to serve is a defining factor in generating credible, generalizable, and ultimately meaningful clinical evidence.”
Meanwhile, in their peer-reviewed article on “Educating for Trust: Reframing Clinical Research Training for Trial Quality, Digital Governance, and Patient Partnership,” Jeroze Dalal, PhD, an independent healthcare consultant in India and former head of clinical operations, governance, and risk management for a major pharmaceuticals firm, and Arghya Biswas, PhD, a Senior Clinical Project Lead working out of Denmark in the pharmaceutical sector, examine how clinical research is undergoing structural transformation driven by decentralized and hybrid trial models, real-world evidence, digital analytics, and artificial intelligence, alongside growing expectations for transparency, equity, and patient partnership.
“We propose that contemporary clinical research education should prioritize three capability domains: ethics by design, governance-aware digital literacy, and meaningful patient partnership,” the authors write. “Ethical reflection should extend across study conception, operational design, and conduct. Digital fluency should encompass data integrity, regulatory implications, and limits of algorithmic inference. Patient partnership should be integrated across trial design and translation of evidence into practice.”
Preparing researchers to steward trust—not merely execute protocols—is essential for sustaining credible and implementation-ready research systems, Dalal and Biswas note.
And in their peer-reviewed article on “A Cross-Sectional Analysis of Clinical Research Participant Satisfaction,” a team of authors led by Holly Bookless, BSN, RN, NE-BC, Nurse Manager with the Clinical Research Center in the College of Medicine at The Ohio State University, explores how measuring the patient experience is vital in healthcare organizations today. Further, they note, because measuring satisfaction clinically is a value-added activity for these organizations, it is meaningful for leaders in clinical research settings to engage in it, as well.
“It has been noted that when considering patient outcomes in clinical trials, the participant experience and satisfaction are sometimes missing from the data or not considered outside the direct intervention,” the authors write. “While patients seek healthcare organizations based on therapeutic need for themselves or their families, those who participate in clinical research may have a different motivating factor. People may volunteer for clinical research based on their healthcare condition; a desire to ‘give back’ by contributing to science; and access to supplies and services, among other reasons.”
Regardless of the rationale, it should be noted that research participants are volunteers and not required to participate in studies, the authors add. “That salient point makes knowing the experience of this population crucial to ensure that research organizations deliver services that promote participant engagement with an overall positive experience,” they write.
Other articles expected to appear in the October 2026 Clinical Researcher include a special feature on “Engaging Vulnerable Populations in Research in Trying Times” by ACRP Fellow Muhammad Waseem, MBBS, MS, FAAP, FACEP, FAHA, FSSH, CPI, FACRP, of Weill Cornell Medicine and Lincoln Medical Center in New York; a peer-reviewed contribution on “Why Women Remain Under-Enrolled in Coronary Artery Disease Trials and What Clinical Research Teams Can Do About It” by Patricia Fitzgerald, MS, from the University of Jamestown in North Dakota; a peer-reviewed look at “Are You Ready for a Clinical Trial Inspection Tomorrow?” from Marc Wartenberger, Vice President for Compliance and Security with CRIO in North Carolina; and a column on the benefits of working with companies that have ISO 27001 certification from Ram Sathia, Founder and CEO of Infiligence, which operates out of California, Canada, and India.
Edited by Gary Cramer
